Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +0.62%66 Price-to-Tangible-Book is 6.01 as of Sep. 07, 2026. GuruFocus rates FRA:PHS with a GF Score™ of 66/100 and a GF Value™ of €7.00 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 837 Drug Manufacturers companies, PhotoCure ASA ranks worse than 81.48% on this metric.
The historical rank and industry rank for PhotoCure ASA's Price-to-Tangible-Book or its related term are showing as below:
FRA:PHS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.65 Med: 6.79 Max: 16.38
Current: 5.95
During the past 13 years, PhotoCure ASA's highest Price to Tangible Book Ratio was 16.38. The lowest was 2.65. And the median was 6.79.
FRA:PHS's Price-to-Tangible-Book is ranked worse than 81.48% of 837
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs FRA:PHS: 5.95
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
PhotoCure ASA Price-to-Tangible-Book Related Terms
PhotoCure ASA Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
PhotoCure ASA (FRA:PHS) has a Price-to-Tangible-Book of 6.01 as of Sep. 07, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #682 out of 837 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is PhotoCure ASA's Price-to-Tangible-Book too high?
PhotoCure ASA's current Price-to-Tangible-Book is 6.01. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.31. PhotoCure ASA's value of 6.01 is 160.2% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #682 out of 837 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PhotoCure ASA has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #682 out of 837 companies for Price-to-Tangible-Book. This places PhotoCure ASA in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.31. PhotoCure ASA's value of 6.01 is 160.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.31, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current Price-to-Tangible-Book of 6.01 is 160.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Price-to-Tangible-Book is 6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.00, compared to a current price of €4.88 — trading 30.4% below its estimated fair value. The current Price-to-Tangible-Book is 6.01 and 160.2% above the Drug Manufacturers industry median of 2.31. PhotoCure ASA's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Price-to-Tangible-Book is 6.01 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €4.88 is trading 30.4% below its estimated GF Value™ of €7.00.
GuruFocus considers PhotoCure ASA to be Significantly Undervalued.
Key valuation signals for FRA:PHS:
Price-to-Tangible-Book: 6.01
GF Value™: €7.00 vs. price of €4.88 (30.4% below fair value)
Industry Position: 160.2% above the Drug Manufacturers median (#682 of 837)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
66GF Score
Get the complete analysis for FRA:PHS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
